{"id":"W1847026520","doi":"10.1200/jco.2009.27.15_suppl.e20514","title":"A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada); Montreal General Hospital","funders":"","keywords":"Medicine; Apixaban; Internal medicine; Cancer; Population; Adverse effect; Surgery; Randomized controlled trial; Vitamin K antagonist; Warfarin; Oncology; Rivaroxaban","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00242308,0.001784939,0.002386034,0.0004483361,0.0004045162,0.001021145,0.0008489746,0.001408683,0.009005182],"category_scores_gemma":[0.002285518,0.0006631242,0.001373695,0.0005113737,0.001030665,0.0007365447,0.0004453927,0.002463694,0.00107615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009496676,"about_ca_system_score_gemma":0.001999834,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009379265,"about_ca_topic_score_gemma":0.002348099,"domain_scores_codex":[0.9990255,0.0006736341,0.00003687757,0.0001097589,0.00005834647,0.00009591931],"domain_scores_gemma":[0.9986839,0.0003328308,0.0003015959,0.00008615811,0.00008833295,0.0005072489],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970469,0.009709174,0.0007432527,0.0006279903,0.000512938,0.00006546643,0.00003711368,0.0003941562,0.002187717,0.000154569,0.001906604,0.013192],"study_design_scores_gemma":[0.953353,0.04494405,0.0006733842,0.00001673517,0.0001213334,0.00003252618,0.000007969463,0.0002144633,0.0001244129,0.0000677825,0.0004386477,0.000005516296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761655,0.003847318,0.0008236847,0.001625106,0.001195321,0.01087114,0.00165322,0.0001590695,0.003659681],"genre_scores_gemma":[0.9711155,0.003015729,0.002228941,0.002505884,0.0009516989,0.01293011,0.002119133,0.00002845937,0.005104565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009005182,"threshold_uncertainty_score":0.03012538,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2903744928873729,"score_gpt":0.6024170944603658,"score_spread":0.3120426015729929,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}